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Human immunodeficiency virus (HIV) Gag proteins are assembled into virus particles and then cleaved by the virion-
associated HIV protease. Concomitant with Gag processing, doughnut-like HIV particles (the immature form) are converted
to particles containing condensed cores (the mature form). Here we describe the in vitro processing of immature HIV Gag
virus-like particles (VLP) by exogenously added HIV protease. Following delipidization, sequential processing of immature
VLP showed that the matrix (MA)/capsid (CA) junction was cleaved faster than the CA/nucleocapsid (NC) junction, an altered
order of processing when compared with authentic processing. When the in vitro processed VLP were analyzed on density
gradients, most of the MA, CA-p15 intermediate, and NC were detected as a highly multimeric form, equivalent to the
unprocessed VLP. In contrast, CA was found as a monomer dissociated from the multimeric CA-p15 following cleavage of
the CA/NC junction. Electron microscopy revealed that the in vitro processing was accompanied by conversion of the
doughnut-like particles to particles containing condensed cores and spherical outer shells. The cores, however, lacked core
shells, which are normally observed for authentic HIV, suggesting that the in vitro processing of immature VLP failed to
produce core shells. © 2000 Academic Press
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MINTRODUCTION
The Gag protein is the main structural component of
retroviral particles and also drives virus particle budding.
The Gag protein of human immunodeficiency virus (HIV)
is synthesized initially as a precursor polyprotein that
self-assembles underneath the plasma membrane to
form the budding virus particle. Just after budding the
particle is often seen as a hollow sphere surrounded by
an electron-dense double ring structure that is com-
posed of multimerized Gag precursors, the immature
form. However, during or after budding (Kaplan et al.,
1994; Vogt, 1996), Gag polyprotein undergoes the pro-
cess termed maturation in which it is cleaved by viral
protease (PR) to yield the N-terminal matrix (MA), the
central capsid (CA), the nucleocapsid (NC), and the C-
terminal p6 proteins (Mervis et al., 1988). Concomitant
with Gag processing, the virus particle adopts a sub-
membrane shell enclosing an electron-dense core sur-
rounded by a core shell. From immunoelectron micro-
scopic examination, it is widely accepted that the sub-
membrane shell is composed of MA protein while the
electron-dense core contains condensed NC protein
with genomic RNA surrounded by the core shell com-
posed of CA protein (Nermut and Hockley, 1996). Expres-
sion of Gag protein alone produces immature virus par-
ticles (Gheysen et al., 1989; Hoshikawa et al., 1991; Smith1 To whom correspondence and reprint requests should be ad-
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366t al., 1993), while that of Gag protein with a PR region
esults in the mature form of the virus particle
Hoshikawa et al., 1991; Karacostas et al., 1989). The
bligatory role for PR in Gag processing and the accom-
anying morphological conversion have been demon-
trated by studies in which expression of Gag with mu-
ated inactive forms of PR fails to cleave Gag proteins
nd results in the production of virus particles arrested at
he immature stage (Gottlinger et al., 1989; Park and
orrow, 1993; Rose et al., 1995).
Since immature retroviruses are noninfectious, the
processing of HIV Gag has been studied extensively as
a target for antiviral therapy. In HIV-infected cells and in
expression systems using Gag recombinant viruses, the
cleavage of the MA/CA, CA/p2, p2/NC, NC/p1, and p1/p6
junctions occurs at different rates, suggesting that each
site is differentially susceptible to cleavage. When the
cleavage sites are made uncleavable by mutation, parti-
cles with aberrant morphologies are produced, suggest-
ing that correct cleavage is essential for virus maturation
(Accola et al., 1998; Gottlinger et al., 1989; Krausslich et
al., 1995; Wiegers et al., 1998). However, it is difficult to
determine the order of Gag processing in cell-based
experiments as the process of virus particle budding and
that of Gag processing are interlinked and neither pro-
cess is synchronized. To overcome this difficulty, in vitro
translated Gag protein has been widely used for cleav-
age studies by exogenously added PR, and these studies
have shown the production of authentic cleavage prod-
ucts, suggesting an order of processing (Krausslich et
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367IN VITRO PROCESSING OF HIV Gag VIRUS-LIKE PARTICLEal., 1998, 1989; Pettit et al., 1994; Tritch et al., 1991).
lthough such systems use authentic substrates for
leavage rather than oligopeptides containing the cleav-
ge site, the morphological conversion of the HIV parti-
le that accompanies Gag processing cannot be fol-
owed. By using a purified source of immature HIV par-
icles as a substrate, however, in vitro processing and
irect observation of the accompanying morphological
hanges might be possible. Here we describe a system
f in vitro processing of immature HIV Gag virus-like
articles (VLP) by exogenously added PR and the cleav-
ge and conversion processes observed.
RESULTS
emoval of the VLP lipid bilayer by detergent
reatment
As Gag proteins enveloped by the lipid bilayer are resis-
ant to protease digestion (Konvalinka et al., 1995; Lee and
u, 1998; Spearman and Ratner, 1996), we disrupted the
ipid bilayer of VLP before assessing Gag processing in
FIG. 1. Gradient analysis of immature and mature forms of VLPs trea
for 30 min before being layered onto 20–70% (w/v) sucrose density gra
for 4 h. Fractions were collected from the bottom to the top (left to righ
MA (C and D) or CA (A, B, E, and F) monoclonal antibodies. (A and B) I
detergent; (panels on the left-hand side) untreated. Lane M, prestaineitro. As Gag shells of immature retroviruses (e.g., avian
eukosis virus and HIV) have been reported to be stable inonionic detergents (Lee and Yu, 1998; Rose et al., 1995;
Stewart et al., 1990), initial membrane permeabilization was
carried out by treatment with 0.5% Triton X-100. When the
delipidized Gag shell of immature HIV VLP was centrifuged
on a 20–70% sucrose density gradient, it passed through
the least dense gradient fractions and migrated further than
the untreated VLP (Figs. 1A and 1B), indicating that unproc-
essed Gag shells were stable in the presence of detergent.
The position of Gag shells in the gradient at a density of
1.22 g/ml compared to 1.17 g/ml for VLP is consistent with
the observations that denuded immature HIV Gag shells
are denser than immature HIV particles with the lipid bi-
layer intact (Lee and Yu, 1998; Lingappa et al., 1997). In
contrast, when the mature form of HIV VLP was treated with
the detergent and similarly centrifuged, MA, CA, and the
MA-CA intermediate (designated p39 in Gowda et al., 1989;
Pettit et al., 1994) were detected in the least dense gradient
fractions by Western blotting using anti-MA (Figs. 1C and
1D) and anti-CA (Figs. 1E and 1F) monoclonal antibodies,
confirming previous reports that the interactions of pro-
h detergent. Purified VLP were adjusted to 0.5% Triton X-100 and held
. Centrifugation was carried out in an SW55 rotor at 4°C at 120,000 g
analyzed by SDS–PAGE followed by Western blotting using anti-HIV-1
re VLP; (C–F) mature VLP. (Panels on the right-hand side) Treated with
cular weight markers (Bio-Rad).ted wit
dients
t) andcessed Gag proteins are sensitive to detergent treatment
(Lee and Yu, 1998; Stewart et al., 1990).
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368 MORIKAWA ET AL.In vitro processing of delipidized VLP
In vitro processing of VLP was performed with the
mmature VLP following treatment with 0.5% Triton X-100.
etergent was removed by dilution with an excess vol-
me of PBS and the Gag shells were re-pelleted by
entrifugation before incubation with recombinant HIV-1
R. To confirm previous studies in which the optimum
ctivity for HIV-1 PR was observed at mildly acidic pH
nd at low salt concentration (Konvalinka et al., 1995),
sequential processing was carried out in buffers of pH 6
or 7 with different concentrations of salt. The products of
digestion were subjected to SDS–PAGE followed by
Western blotting using anti-MA (Fig. 2, top) and anti-CA
antibodies (Fig. 2, bottom). Under all conditions tested,
the MA domain was promptly released (Fig. 2, top) while,
in contrast, CA(p24) and CA-p2(p25) were more gradually
released concomitant with the disappearance of the pro-
cessing intermediate CA-p15 (designated p40 in Pettit et
al., 1994) that was identified both by the absence of
reactivity with anti-MA antibody (Fig. 2, top) and by the
reactivity with an anti-p6 peptide serum (data not shown).
The reaction carried out at pH 6 in 150 mM salt was
essentially complete by 2 h post-PR addition (Fig. 2A).
However, the reaction was retarded by a high concen-
tration of salt (Fig. 2B). Severe retardation of cleavage
was observed at pH 7 and no mature CA(p24) was
FIG. 2. Sequential processing of Gag shells by PR in vitro under diffe
diluted with 10 vol of PBS, and centrifuged at 4°C at 150,000 g for 2 h. T
(pH 6.0), 150 mM NaCl, 1 mM DTT, and 1 mM EDTA (A), in buffer cont
or in buffer containing 50 mM HEPES (pH 7.0), 150 mM NaCl, 1 mM DTT
in 100 ml of buffer (described above) containing 35–40 mg of Gag and
etected by Western blotting using anti-HIV-1 MA (top) and CA (bot
igestion; 2–8, digested for 3, 10, 30, 60, 120, 240, and 480 min, respeproduced throughout the digestion period (Fig. 2C, bot-
tom). Thus, as the digestion of Gag shells at neutral pHresulted in incomplete processing, all further study of in
vitro processing was performed at pH 6 in 150 mM salt.
To investigate the multimeric states of the processed
Gag proteins, the in vitro processing products were cen-
trifuged on 20–70% sucrose density gradients and de-
tected by Western blotting using anti-MA and anti-CA
antibodies (Fig. 3). Most of the MA protein was found in
the same fractions as the unprocessed Gag shells fol-
lowing removal of the lipid bilayer, indicating that MA
molecules was retained in a highly multimeric form,
although a trace of MA was found in the least dense
fractions (Fig. 3A). When probed with anti-CA antibody,
most of the processing intermediate was also observed
as a highly multimeric form, as was a small fraction of the
processed CA protein. Most of the CA protein, however,
was found in the least dense fractions, suggesting that
although some CA molecules existed in a highly multi-
meric form, the majority of the CA molecules were re-
leased as low-molecular-weight forms by PR digestion
(Fig. 3B, top). The dissociated form of CA accumulated
during the course of the reaction while, in contrast, the
multimeric forms of the processing intermediates and
those of the CA molecules were reduced (Fig. 3B, bot-
tom). When the in vitro products were subjected to sed-
imentation analysis on a 15–30% glycerol gradient and
compared with molecular mass markers sedimented in
nditions. Immature VLP were treated with 0.5% Triton X-100 for 30 min,
idized Gag shells were resuspended in buffer containing 50 mM MES
50 mM MES (pH 6.0), 500 mM NaCl, 1 mM DTT, and 1 mM EDTA (B),
mM EDTA (C). Digestion by purified HIV-1 PR was carried out at 37°C
g of PR (Gag-to-PR molar ratio of 30:1). The digested products were
anes: M, prestained molecular weight markers (Bio-Rad); 1, prior torent co
he delip
aining
, and 1
250 nparallel (Fig. 4), the calculated molecular mass of the
dissociated CA protein was 24–25 kDa, equivalent to the
T
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369IN VITRO PROCESSING OF HIV Gag VIRUS-LIKE PARTICLEmonomeric form, not the dimeric form (Fig. 4C). These
results suggest that (1) CA domains were released
largely as monomers from highly multimeric processing
intermediates after cleavage of the CA/NC junction and
(2) the multimeric CA species were only transient forms
of CA during the in vitro processing reaction. As an
informative anti-NC antibody was not available, the sedi-
mented position of the NC protein in a 20–70% sucrose
gradient was detected directly by silver staining. The NC
protein was found in the same fractions as the MA
protein and the processing intermediate, suggesting that
the NC protein also exists in a highly multimeric form
(Fig. 3C). Visible in the lightest fractions of the gradient
was a 6-kDa protein, probably the C-terminal p6 domain.
When in vitro processing was carried out at pH 7 or at
high salt concentration and similarly analyzed on 20–70%
sucrose gradients, no significant differences were ob-
served in the sedimentation profiles (data not shown).
To examine the possibility that the observed dissoci-
ation of CA protein during the processing reaction may
be due to trace amounts of the detergent remaining in
the Gag shell preparation, delipidization was also per-
formed by extraction with ether and followed by similar
digestion with PR. The pattern of sequential processing
as identified by anti-MA and anti-CA antibodies was
similar to that shown for detergent-extracted Gag (data
not shown). When the in vitro processed Gag shell was
sedimented through a 20–70% sucrose gradient, the pro-
files were found to be similar to those of the Gag shell
digested by PR after the detergent treatment (Fig. 5). The
MA protein (Fig. 5B), the processing intermediate (Fig.
5C), and the NC protein (Fig. 5D) were found as highly
multimeric forms while, in contrast, the CA protein was
FIG. 3. Gradient analysis of in vitro processed Gag shells. Preparatio
2. The Gag shells were resuspended in buffer containing 50 mM MES
PR at 37°C for 30 min (top) or 2 h (bottom) in 100-ml reaction mixtures
he digested products were applied to 20–70% (w/v) sucrose gradients
he bottom to the top (left to right) were analyzed by SDS–PAGE and
onoclonal antibodies or to silver staining (C). Lane M, prestained mopresent only in the lightest gradient fractions (Fig. 5C).
These results indicate that the dissociation of CA fromthe Gag shell following in vitro processing is not due to
the residual detergent in the shell preparation but rather
to the lack of a stable interaction between the CA do-
mains after PR processing.
Detergent sensitivity of in vitro processed VLP
As Gag–gag interactions of authentic mature virions
are sensitive to 0.5% Triton X-100 (cf. Fig. 1), the effect of
detergent addition to the in vitro processed VLP was
examined. The highly multimeric forms of Gag following
in vitro processing were recovered from the relevant
gradient fractions and re-pelleted by centrifugation. Fol-
lowing the addition of 0.5% Triton X-100, the Gag prepa-
ration was reanalyzed on a 20–70% sucrose density
gradient. Fractionation of the gradient showed that all the
multimeric MA, processing intermediate, and CA were
dissociated (Figs. 6A and 6B), similar to the disruption of
mature VLP by the detergent treatment (compare to Figs.
1D and 1E, respectively). This finding suggests, although
it does not prove, that multimeric Gag proteins pro-
cessed in vitro and in vivo are structurally and organiza-
tionally similar. By contrast, when delipidized Gag shells
were not digested by PR, further treatment with 0.5%
Triton X-100 did not disrupt the highly multimeric state of
Gag proteins (Fig. 6C).
Morphological conversion of VLP by in vitro
processing
Electron microscopic analysis of the products of the in
vitro digestion reaction was done to examine whether
the material had a defined structure and/or similarity to
mature HIV. The Gag shell delipidized by treatment with
lipidized Gag shells was performed as described in the legend to Fig.
0), 150 mM NaCl, 1 mM DTT, and 1 mM EDTA and digested by HIV-1
ing 35–40 mg of Gag and 250 ng of PR (Gag-to-PR molar ratio of 30:1).
entrifuged in an SW55 rotor at 4°C at 120,000 g for 4 h. Fractions from
bjected either to Western blotting using anti-HIV-1 MA (A) or CA (B)
r weight markers (Bio-Rad in A and B or Life Technologies in C).n of de
(pH 6.
contain
and c0.5% Triton X-100 showed a hollow sphere surrounded by
a double ring structure (Fig. 7B), typical of untreated
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370 MORIKAWA ET AL.immature VLP (Fig. 7A), and confirmed that unprocessed
Gag shells were intact following detergent treatment.
The Gag shells were not highly aggregated in our prep-
arations, consistent with studies on avian leukosis virus
(Stewart et al., 1990). When the in vitro processing prod-
cts were similarly analyzed, no double ring structures
ere present but round electron-dense structures, likely
orresponding to a complex of NC (possibly including
A-p15) and RNA, were observed (Figs. 7C and 7D). The
tructures were embedded in, and attached to, partially
isrupted spherical shells (Fig. 7C, arrowheads), which
ay correspond to a multimer of predominantly MA,
lthough this is not proven. A high degree of aggregation
etween the shells was frequently visible (Fig. 7C, right).
haracteristic of most of the cores was the absence of
FIG. 4. Sedimentation analysis to determine the molecular masses of
the dissociated mature Gag proteins following in vitro processing.
Delipidization and digestion of Gag VLP were performed as described
in the legends to Figs. 2 and 3, respectively. The 2-h digested products
were subjected to velocity sedimentation analysis on 15–30% (v/v)
glycerol gradients. Centrifugation was carried out in an SW55 rotor at
4°C at 230,000 g for 40 h. Fractions from the bottom to the top (left to
ight) were analyzed by SDS–PAGE followed by Western blotting using
nti-HIV-1 MA (B) or CA (C) monoclonal antibodies. Molecular mass
arkers (a low-molecular-weight calibration kit, Amersham Pharmacia
iotech) were sedimented in parallel and stained with Coomassie
rilliant blue (A). Lane M, prestained molecular weight markers (Bio-
ad) for SDS–PAGE.ore shells that were normally observed in mature HIV
ores (compare Figs. 7D and 7E). The occasional corehell visualized at a low frequency was neither conical
or rod-shaped (Fig. 7C, arrow). No core shells were
isible when the processing reaction went to completion,
onditions under which the majority of the CA molecules
ere dissociated to monomers (data not shown). To-
ether, these results suggest that the in vitro processing
f Gag shells allowed formation of condensed cores and
uter shells but did not routinely produce core shells.
DISCUSSION
Despite reports that immature forms of avian retroviral
nd HIV particles could be cleaved by exogenous PR in
FIG. 5. Gradient analysis of in vitro processed Gag shells following
delipidization by ether treatment. Immature VLP were extracted with 2
vol of ether for 30 min and pelleted by centrifugation at 4°C at 150,000
g for 2 h. Digestion of the delipidized Gag shells was carried out as
described in the legend to Fig. 3. The undigested and 30-min digested
samples were layered onto 20–70% (w/v) sucrose gradients and cen-
trifuged in an SW55 rotor at 4°C at 120,000 g for 4 h. Fractions from the
bottom to the top (left to right) were analyzed by SDS–PAGE followed
either by Western blotting using anti-HIV-1 MA (B) or CA (A and C)
monoclonal antibodies or by silver staining (D). (A) Unprocessed; (B–D)
processed. Lane M, prestained molecular weight markers (Bio-Rad in
A–C or Life Technologies in D).
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371IN VITRO PROCESSING OF HIV Gag VIRUS-LIKE PARTICLEthe presence of detergent (Stewart et al., 1990; Kon-
alinka et al., 1995), the morphological analysis of such
rocessed particles has not been previously shown. In
his paper we performed in vitro processing of immature
IV VLP by exogenous PR following removal of the re-
gents used for delipidization and observed the struc-
ural transformation of the VLP associated with the cleav-
ge reaction. In parallel, we analyzed the multimeric
ature of the in vitro cleavage products by density gra-
dient analysis. We found that, in the system, the MA/CA
junction was cleaved faster than the CA/NC junction,
accompanied by a failure to form core shells. By contrast,
although incomplete, outer shells and cores still formed.
It is difficult to assess the real order of Gag processing
in virus particles budded from infected cells. Indeed, Gag
FIG. 6. Gradient analysis of detergent-treated Gag products following
in vitro processing. Delipidization and digestion of Gag VLP were
performed as described in the legend to Figs. 2 and 3, respectively. The
30-min digested products were centrifuged on 20–70% (w/v) sucrose
gradients as described in the legend to Fig. 3 and highly multimeric
forms of Gags were collected from the relevant gradient fractions. The
highly multimeric Gag products were subjected to another treatment
with 0.5% Triton X-100 for 30 min and centrifuged on 20–70% (w/v)
sucrose gradients in an SW55 rotor at 4°C at 120,000 g for 4 h.
Fractions from the bottom to the top (left to right) were analyzed by
SDS–PAGE followed by Western blotting using anti-HIV-1 MA (A) or CA
(B and C) monoclonal antibodies. (A and B) Processed; (C) unpro-
cessed. Lame M, prestained molecular weight markers (Bio-Rad).processing is seen even in the cytoplasm (Kaplan and
Swanstrom, 1991), although processed Gag proteins maynot participate in virus particle formation since it has
been reported that premature processing in the cyto-
plasm by overexpression of PR leads to no virus particle
production (Karacostas et al., 1993; Krausslich, 1991;
Park and Morrow, 1991). Nevertheless, recent mutational
analyses on the cleavage sites suggest an order of Gag
processing based on the morphologies of the virus par-
ticles arrested at various stages during the maturation
process (Accola et al., 1998; Gottlinger et al., 1989; Kraus-
slich et al., 1995; Wiegers et al., 1998). Although an
alteration of the Gag conformation by the mutations in-
troduced in those studies cannot be ruled out, the data
suggest that cleavage at the p2/NC junction is the first
event for NC condensation and is followed by the MA/CA
cleavage, leading to formation of a submembrane shell.
Formation of a core shell has been suggested to be
triggered by cleavage at the MA/CA junction and com-
pleted by cleavage at the CA/p2 junction (p2/NC . MA/
CA . CA/p2). In vitro processing studies in which in vitro
translated Gag protein was utilized as a substrate also
support this order. These studies have shown that Gag
protein is initially cleaved at the p2/NC junction, followed
by cleavage at the MA/CA junction, and finally cleavage
at the CA/p2 junction (p2/NC . NC/p6 $ MA/CA .
CA/p2) (Pettit et al., 1994; Tritch et al., 1991). However, we
observed a different order of Gag processing (MA/CA .
p2/NC . CA/p2). Stewart and Vogt (1994) have proposed
a structural model for in vitro processing of retroviral
particles, in which the MA/CA junction may be cleaved
initially because PR approaches Gag shells from the
outside. Our studies support this view, since our order
did not change even when the reaction was carried out
at different pH values or salt concentrations, suggesting
that alteration of the order in in vitro processing is not
due to altered binding affinity of PR but rather to physical
distances to each of the cleavage sites.
It is interesting that the altered order of Gag process-
ing allowed outer shell formation and core condensation
even though their architectures were aberrant. Recent
ultrastructural studies of immature HIV particles have
suggested that Gag precursors form a fullerene-like par-
ticle structure composed of hexamers with pentamers
(Nermut et al., 1994) or a cage-like structure (Fuller et al.,
1997). Although little is known of how Gag processing
leads to collapse of the double ring structure composed
of Gag precursors and reassembly to yield the individual
Gag architectures of the mature particles, Nermut and
Hockley (1996) have suggested that following Gag pro-
cessing, multimers of CA are dissociated into monomers
before reassembly into the conical core shell while, in
contrast, those of MA remain associated. We reason that
this might lead to a failure of core shell formation but
allow outer shell formation in our system although it
remains unproven that our observed outer shell was a
layer of MA. A failure of core shell formation was also
observed when in vitro assembled Gag particles were
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372 MORIKAWA ET AL.subjected to in vitro processing (Gross et al., 1998).
Recent crystallographic studies have demonstrated trim-
erization of MA (Hill et al., 1996; Rao et al., 1995) and, in
ontrast, dimerization of CA (Berthet-Colominas et al.,
999; Gamble et al., 1996, 1997; Momany et al., 1996; von
Schwedler et al., 1998), suggesting that the cleavage at
he MA/CA junction plays a key role for morphological
onversion of core shells from spheres to cones (Gamble
t al., 1997; von Schwedler et al., 1998). It is possible that
he in vitro processing described here might fail to redi-
ect an assembly state of CA.
MATERIALS AND METHODS
ells and viruses
For the immature form of HIV VLP, spodoptera frugi-
erda (Sf9) cells were inoculated with a recombinant
utographa californica nuclear polyhedrosis virus (bac-
ulovirus) containing the full-length HIV-1 (IIIB strain) gag
gene (Morikawa et al., 1996) and cultured at 27°C in
TC-100 medium (Life Technologies) supplemented with
10% fetal bovine serum (FBS). For the mature form of HIV
VLP, RK-13 cells were infected with a recombinant vac-
cinia virus containing the full-length HIV-1 (IIIB strain)
gag-pol gene (Hoshikawa et al., 1991) and cultured at
37°C in Eagle’s minimum essential medium (Life Tech-
nologies) supplemented with 5% FBS.
Purification of HIV VLP
HIV VLP were purified from culture medium of cells
infected with recombinant viruses and finally resus-
pended in PBS. The purification procedure was de-
scribed elsewhere (Morikawa et al., 1996).
Removal of viral lipid bilayer and in vitro processing
by HIV PR
To remove the lipid bilayer of HIV VLP, the purified VLP
was treated with 0.5% Triton X-100 or 2 vol of ether at
room temperature for 30 min. Following dilution with 10
vol of PBS, the denuded Gag shell of immature VLP was
pelleted by centrifugation at 4°C at 150,000 g for 2 h. For
in vitro processing, the Gag shell was resuspended with
50 mM MES (pH 6.0), 150 mM NaCl, 1 mM DTT, and 1
mM EDTA unless otherwise indicated. Digestion was
carried out with purified HIV-1 PR (Roche Discovery,
Welwyn, UK) at 37°C for the indicated time (see legends
The 30-min digested products were observed by electron microscopy.
(A) Immature VLP; (B) delipidized but unprocessed Gag shells; (C and
D) delipidized and processed Gag shells; (E) authentic HIV-1 (LAV1
strain) particles. An arrowhead shows a particle containing an partially
disrupted outer shell and an electron-dense core. Note the absence of
a core shell in most of the in vitro digested particles. An arrow showsFIG. 7. Electron microscopic examination of unprocessed and in vitroparticle containing an outer shell and an electron-dense core sur-
ounded by a core shell. All micrographs are at same magnification.
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373IN VITRO PROCESSING OF HIV Gag VIRUS-LIKE PARTICLEto figures) in 100-ml reaction mixtures containing 35–40
mg of Gag and 250 ng of HIV-1 PR (Gag-to-PR molar ratio
of 30:1) and stopped by addition of pepstatin A. In some
experiments, in vitro processed Gag shell was again
treated with 0.5% Triton X-100 (see legend to Fig. 6).
Gradient analysis
Unprocessed and processed Gag shells were applied
onto 20–70% (w/v) sucrose density gradients in PBS and
centrifugal in an SW55 rotor (Beckman) at 4°C at 120,000
g for 4 h, conditions under which the Gag shells reached
equilibrium density. Alternatively, processed Gag shells
were applied onto 15–30% (v/v) glycerol gradients in 20
mM Tris (pH 7.4) and 100 mM NaCl and sedimented in an
SW55 rotor at 4°C at 230,000 g for 40 h. A low-molecular-
eight calibration kit (Amersham Pharmacia Biotech)
as used for molecular mass markers in the latter ex-
eriment.
rotein detection
Protein samples were analyzed by electrophoresis on
DS–PAGE on 14% acrylamide. Western blotting (Towbin
t al., 1979) was carried out using anti-HIV-1 MA or CA
onoclonal antibody (Medical Research Council AIDS
eagent Repository, National Institute for Biological
tandards and Control, Herz, UK) and anti-mouse IgG
lkaline phosphatase conjugate (Cappel). To detect NC
nd p6, protein samples were analyzed by SDS–PAGE on
6% acrylamide and subjected to silver staining.
lectron microscopy
The procedure for microscopic examination was de-
cribed previously (Goto et al., 1990). Briefly, HIV VLPs
nd in vitro processed Gag shells were collected by
centrifugation and fixed with 2% glutaraldehyde in 50 mM
cacodylate buffer (pH 7.2) at 4°C for 2 h prior to treatment
with 1% osmium tetroxide in 50 mM cacodylate buffer
(pH 7.2) at 4°C for 1 h. Ultrathin sections were stained
with uranyl acetate and lead citrate. Authentic mature
HIV particles were similarly prepared from culture me-
dium of MOLT4/HIV-1 (LAV1 strain) cells.
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